Just follow the link in this email.
novomedlink logo
Congratulation‌s, [Name]!
Thank you for participating in Novo Nordisk’s insulin pen training. This email confirms that you’ve successfully completed the [Brand name] [device] training and earned your [Brand name] [device] training certificate.
 View certificate 
NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 Units/mL Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL Fiasp® (insulin aspart injection) 100 U/mL Levemir® (insulin detemir injection) 100 U/mL NovoLog® (insulin aspart injection) 100 U/mL
You may return to insulin pen training any time to earn additional certificates or refresh your skills. Or visit novomedlink.com to explore:
  • Key information for all Novo Nordisk products
  • A broad selection of patient education materials
  • Patient savings and coverage information
PLEASE DO NOT RESPOND TO THIS EMAIL.
If you would like to contact us, please click here or call 1‑877‑744‑2579.
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536
Fiasp®, FlexPen®, FlexTouch®, Levemir®, NovoLog®, NovoLog® Mix 70/30, and Tresiba® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk  All rights reserved.  US21DI00012  May 2021		 Novo Nordisk logo.
Novo Nordisk logo.